RO7795081

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

15 competitors in Renal Impairment

#DrugCompanyPhaseTrials

1

Zyvox

Pfizer

Approved

12

Fludara

Sanofi

Phase 1

13

Grafapex

MMedexus Pharma, Inc.

Phase 1

14

Nemtabrutinib

Merck & Co.

Phase 1

15

Wayrilz

GGenzyme, a Sanofi Company

Phase 1

16

GZR18

GGan & Lee Pharmaceuticals.

Phase 1

17

D-2570

IInventisBio Co., Ltd

Phase 1

18

ASTX727

Taiho Oncology, Inc.

Phase 1

19

Sulthiame

Roche

Phase 1

110

PKN605

Novartis

Phase 1

1Show 6 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity or Overweight1 trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 38 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

Completed·Roche·Phase 2·NCT07081958·352 enrolled

Renal Impairment1 trial

A Two-part, Non-randomized, Open-label, Parallel-group Study to Assess the Effect of Renal Impairment on the Pharmacokinetics and Safety of RO7795081 Following a Single Oral Dose of RO7795081

Recruiting·Roche·Phase 1·NCT07741604·60 enrolled

Type 2 Diabetes Mellitus1 trial

A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus

Active, not recruiting·Roche·Phase 2·NCT07112872·330 enrolled

Obesity1 trial

A Phase I, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Fixed-Sequence Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Orally Administered RO7795081 and the Effect of Steady-State Dose of Orally Administered RO7795081 on the Pharmacokinetics of Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants

Active, not recruiting·Roche·Phase 1·NCT06982131·40 enrolled

Overweight or Obesity1 trial

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

Active, not recruiting·Roche·Phase 1·NCT07499050·30 enrolled

1 more indication

Unspecified1 trial

An Open-Label, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Itraconazole, Multiple Oral Doses of Gemfibrozil, and Single Oral Dose of Cyclosporine, on the Pharmacokinetics of a Single Oral Dose of RO7795081 in Healthy Participants

Completed·Roche·Phase 1·NCT06809608·36 enrolled

Details

Drug Info

Related News